This site is intended for Healthcare professionals only.

Mortality doubles in CKD patients due to accompanying Pulmonary Hypertension


Mortality doubles in CKD patients due to accompanying Pulmonary Hypertension

A substantial number of patients with CKD develops Pulmonary Hypertension, the mortality rate being twice among those with PH as compared to those without PH, according to a recent study published in Indian Journal of Nephrology.

Pulmonary hypertension (PH) is a condition of increased blood pressure within the arteries of the lungs. Symptoms include shortness of breath, syncope, tiredness, chest pain, swelling of the legs, and a fast heartbeat. It is an overlooked cardiovascular complication of CKD especially in end‑stage renal disease (ESRD). It has prevalence estimates of 30%–50% and is an independent predictor of increased mortality in CKD patient.

Dr.B. S. Arun and his associates conducted a study to analyze the prevalence of PH in patients with CKD, its severity in different stages of CKD, and risk factors for it

One hundred and eight patients with CKD treated at Karnataka Institute of Medical Sciences for six months between January 1, 2014, and June 30, 2015, were included in the study. Clinical evaluation and relevant investigations including echocardiography were done. Follow‑up echocardiography was done at 3 and 6 months and assessed. PH was present in 47 of 108 (43.5%) cases at the beginning, 41 of 83 (491.4%) at 3 months, and 32 of 64 (50%) at 6 months. The prevalence and severity of PH increased with progression of CKD stage, although not statistically significant.

The study found that heart failure with reduced ejection fraction(HFrEF) and heart failure with preserved ejection fraction(HFpEF) was significantly higher among PH group compared to the non‑PH group. Mean hemoglobin in PH group was significantly lower, compared to the non‑PH group. The majority of them had moderate PH at the beginning of the study which remained same, despite being on hemodialysis.

The study concluded that a substantial number of the patients with CKD develops PH. HFrEF and HFpEF are the strongest risk factors. The other factors contributing to it are anemia, volume overload, and increased calcium phosphate product. Thus, PH can be considered as a reflection of cardiorenal syndrome type 4. The other factors contributing to it are anemia, volume overload, and increased calcium phosphate product.

The article was published in Indian Journal of Nephrology.

For more reference log on to 10.4103/ijn.IJN_36_17

The following two tabs change content below.
Vinay Singh

Vinay Singh

Vinay Singh joined Medical Dialogue as Desk Editor in 2018. He covers the medical speciality news in different medical categories including Medical guidelines, updates from Medical Journals and Case Reports. He completed his graduation in Biotechnology from AAIDU and did his MBA from IILM Gurgaon. He can be contacted at editorial@medicaldialogues.in . Contact no. 011-43720751
Source: With inputs from Indian Journal of Nephrology

Share your Opinion Disclaimer

Sort by: Newest | Oldest | Most Voted